Gaviscon Liquid - Peppermint Flavour
*Company:
Reckitt Benckiser Ireland LimitedStatus:
No Recent UpdateLegal Category:
Supply through general saleActive Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 14 September 2021
File name
Gaviscon Liquid Peppermint Flavour PIL.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Updated on 18 June 2021
File name
Gaviscon Liquid Peppermint Flavour.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.9 - Overdose
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Addition of information regarding sodium content.
Rewording of Sect 4.9
Updated on 15 January 2020
File name
Gaviscon Liquid Peppermint.pdf
Reasons for updating
- New PIL for new product
Updated on 02 September 2014
Reasons for updating
- New SPC for new product
Legal category:Supply through general sale
Updated on 02 September 2014
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 4.2 - added information for special patient groups
Section 4.3 - added contraindications for hypersensitivity to the active substances or excipients
Section 4.4 - Added additional precautions
Section 4.5 - added a time interval between taking Gaviscon and other medicinal products
Section 4.6 - Change to the format of section and an update to the information for taking Gaviscon during pregnancy
Section 4.7 - Editorial change
Section 4.8 - Update to layout of frequency of adverse events and addition of reporting of adverse reactions
Section 5.1 - addition of ATC code and pharacotherapeutic group
Section 10 - updated date of revision of the text
Section 4.3 - added contraindications for hypersensitivity to the active substances or excipients
Section 4.4 - Added additional precautions
Section 4.5 - added a time interval between taking Gaviscon and other medicinal products
Section 4.6 - Change to the format of section and an update to the information for taking Gaviscon during pregnancy
Section 4.7 - Editorial change
Section 4.8 - Update to layout of frequency of adverse events and addition of reporting of adverse reactions
Section 5.1 - addition of ATC code and pharacotherapeutic group
Section 10 - updated date of revision of the text
Updated on 02 September 2014
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Section 4.2 - added information for special patient groups
Section 4.3 - added contraindications for hypersensitivity to the active substances or excipients
Section 4.4 - Added additional precautions
Section 4.5 - added a time interval between taking Gaviscon and other medicinal products
Section 4.6 - Change to the format of section and an update to the information for taking Gaviscon during pregnancy
Section 4.7 - Editorial change
Section 4.8 - Update to layout of frequency of adverse events and addition of reporting of adverse reactions
Section 5.1 - addition of ATC code and pharacotherapeutic group
Section 10 - updated date of revision of the text
Section 4.3 - added contraindications for hypersensitivity to the active substances or excipients
Section 4.4 - Added additional precautions
Section 4.5 - added a time interval between taking Gaviscon and other medicinal products
Section 4.6 - Change to the format of section and an update to the information for taking Gaviscon during pregnancy
Section 4.7 - Editorial change
Section 4.8 - Update to layout of frequency of adverse events and addition of reporting of adverse reactions
Section 5.1 - addition of ATC code and pharacotherapeutic group
Section 10 - updated date of revision of the text
Updated on 13 December 2012
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
In section 4.4, added " Contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions."
Updated on 13 December 2012
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Free text change information supplied by the pharmaceutical company
In section 4.4, added " Contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions."
Updated on 10 December 2012
Reasons for updating
- Change to section 6.4 - Special precautions for storage
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
In section 6.4, "do not refrigerate" has been added.
In section 10, the date of revision of the text has been updated to November 2012.
In section 10, the date of revision of the text has been updated to November 2012.
Updated on 10 December 2012
Reasons for updating
- Change to section 6.4 - Special precautions for storage
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 6.4, "do not refrigerate" has been added.
In section 10, the date of revision of the text has been updated to November 2012.
In section 10, the date of revision of the text has been updated to November 2012.
Updated on 15 May 2007
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 4.8. Allergic manifestations expanded to include anaphylactic and anaphylactoid reactions.
Section 7. Change of marketing authorisation holder address to: 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
Updated on 15 May 2007
Reasons for updating
- Change to section 4.8 - Undesirable effects
Free text change information supplied by the pharmaceutical company
Section 4.8. Allergic manifestations expanded to include anaphylactic and anaphylactoid reactions.
Section 7. Change of marketing authorisation holder address to: 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
Updated on 09 August 2006
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 6.3 - Shelf life
- Change to section 6.5 - Nature and contents of container
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Changes to pack sizes in sections 4.1, 4.2, 4.4 and 6.5. Pack sizes of 200 and 300ml have been removed from the sections denoting packs for retail sale through pharmacies only and a 300 ml pack has been added to the sections denoting packs for general sale.
Reduction in shelf-life from three years to two years in section 6.3
Updated on 09 August 2006
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 6.3 - Shelf life
- Change to section 6.5 - Nature and contents of container
Free text change information supplied by the pharmaceutical company
Changes to pack sizes in sections 4.1, 4.2, 4.4 and 6.5. Pack sizes of 200 and 300ml have been removed from the sections denoting packs for retail sale through pharmacies only and a 300 ml pack has been added to the sections denoting packs for general sale.
Reduction in shelf-life from three years to two years in section 6.3
Updated on 01 July 2005
Reasons for updating
- Change to section 4.2 - Posology and method of administration
Legal category:Supply through general sale
Updated on 01 July 2005
Reasons for updating
- Change to section 4.2 - Posology and method of administration
Updated on 19 May 2005
Reasons for updating
- Improved electronic presentation
Legal category:Supply through general sale
Updated on 19 May 2005
Reasons for updating
- Improved electronic presentation
Updated on 10 August 2004
Reasons for updating
- New SPC for medicines.ie
Legal category:Supply through general sale
Updated on 10 August 2004
Reasons for updating
- New SPC for medicines.ie